eli lilly posted thirdquarter earnings of 194 a share 2 cents below analysts’ estimates but the stock was rising after the drug giant boosted its fullyear guidance eli lilly‘s revenue in the third quarter was 677 billion analysts expected sales of 664 billion the company also said that it had begun submitting its alzheimer’s disease